Copeptin作为代谢性疾病生物标志物的研究进展

Research progress on Copeptin as a biomarker of metabolic diseases

精氨酸加压素是一种由下丘脑合成以应对血浆渗透压增加和血容量减少的激素,它可以与精氨酸加压素受体结合影响糖脂代谢。最近有研究表明,Copeptin是一个稳定、敏感且暂未发现有生物活性的精氨酸加压素替代标志物,与精氨酸加压素以等摩尔量释放入血,其循环水平升高与糖尿病、糖尿病并发症、肥胖、胰岛素抵抗、高血压、高脂血症、非酒精性脂肪性肝病等代谢性疾病密切相关。积极探索Copeptin与代谢性疾病中的关系有助于疾病的早期诊断。

Arginine vasopressin(AVP)is a hormone synthesized from the hypothalamus in response to increased plasma osmotic pressure and decreased blood volume, which influences glucolipid metabolism by binding to AVP receptors. Recent studies show that Copeptin, co-secreted with AVP in equimolar amounts, is considered stabilized, sensitive and not bioactive surrogate marker of AVP.Elevated plasma levels of Copeptin are essentially associated with diabetes, diabetic complications, obesity, insulin resistance, hypertension, hyperlipidemia, non-alcoholic fatty liver disease and other metabolic diseases. Therefore, exploring the relationship between Copeptin and metabolic diseases actively will contribute to the early diagnosis of related diseases.